LFTD Partners (LIFD) 10-K 30 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 23, 2020	Jun. 30, 2019
Document and Entity Information:
Registrant Name	ACQUIRED SALES CORP.
Registrant CIK	0001391135
SEC Form	10-K
Period End date	Dec. 31, 2019
Fiscal Year End	--12-31
Tax Identification Number (TIN)	87-0479286
Number of common stock shares outstanding		6,627,124
Public Float			$ 8,779,755
Filer Category	Non-accelerated Filer
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Small Business	true
Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity File Number	000-52102
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Incorporation, State Country Code	NV
Entity Address, Address Line One	31 N. Suffolk Lane, Lake Forest, Illinois
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60045
City Area Code	847
Local Phone Number	915-2446

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash and Cash Equivalents	$ 4,384,929	$ 0
Prepaid Expenses	9,583	0
Note Receivable from CBD LION	200,000	0
Total Current Assets	4,594,512	0
Investment in Ablis	399,200	0
Investment in Bendistillery and Bend Spirits	1,497,000	0
Total Assets	6,490,712	0
Accounts Payable - Related Party
Accounts Payable - Related Party - Payable to William C. Jacobs	0	164,417
Accounts Payable - Related Party - Payable to Gerard M. Jacobs	0	24,583
Accounts Payable - Related Party - Payable to Other Related Party	0	4,000
Accounts Payable - Related Party	0	193,000
Accounts Payable	38,485	113,450
Notes Payable - Payable to Joshua A. Bloom	0	20,025
Notes Payable - Payable to Gerard M. Jacobs	0	10,766
Notes Payable - Related Party	0	30,791
Interest - Payable to Joshua A. Bloom	0	914
Interest - Payable to Gerard M. Jacobs	0	467
Interest Payable - Related Party	0	1,381
Preferred Stock Dividends Payable
Series A Convertible Preferred Stock Dividends Payable	145,017	0
Series B Convertible Preferred Stock Dividends Payable	5,741	0
Preferred Stock Dividends Payable	150,758	0
Total Current Liabilities	189,243	338,622
Commitments and Contingencies	0	0
Shareholders' Equity
Preferred stock	166	0
Common Stock, $0.001 par value; 100,000,000 shares authorized; 2,726,669 and 2,369,648 shares outstanding at December 31, 2019 and December 31, 2018, respectively	2,727	2,370
Additional paid-in capital	21,691,128	13,664,697
Accumulated Deficit	(15,392,552)	(14,005,689)
Total Shareholders' Equity (Deficit)	6,301,469	(338,622)
Total Liabilities and Shareholders' Equity	$ 6,490,712	$ 0

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred Stock, par or stated value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Common Stock, par or stated value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares outstanding	2,726,669	2,369,648
Series A Convertible Preferred Stock
Preferred Stock, par or stated value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	400,000	400,000
Preferred Stock, shares issued	66,150	0
Preferred Stock, shares outstanding	66,150	0
Series B Convertible Preferred Stock
Preferred Stock, par or stated value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares issued	100,000	0
Preferred Stock, shares outstanding	100,000	0

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Selling, General and Administrative Expenses	$ (64,734)	$ (11,299)
Stock Compensation Expense	(874,154)	(72,500)
Consulting and Independent Contractor Fees	(112,500)	(60,000)
Professional Fees	(211,543)	(37,767)
Loss From Operations	(1,262,931)	(181,566)
Gain on Settlement	29,196	0
Interest Income	25,628	0
Interest Expense	(27,998)	(39,055)
Total Other Income	26,826	(39,055)
Loss Before Provision for Income Taxes	(1,236,105)	(220,621)
Provision for Income Taxes	0	0
Net Loss	$ (1,236,105)	$ (220,621)
Basic and Diluted Net Loss per Share	$ (0.48)	$ (0.09)
Basic and Diluted Weighted Average Number of Common Shares Outstanding:	2,577,349	2,369,648

STATEMENTS OF SHAREHOLDERS' EQU

STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2017		$ 2,370	$ 13,554,524	$ (13,785,068)	$ (228,174)
Shares, Outstanding, Beginning Balance at Dec. 31, 2017		2,369,648
Net Loss				(20,068)	(20,068)
Stockholders' Equity Attributable to Parent, Ending Balance at Mar. 31, 2018		$ 2,370	13,554,524	(13,805,136)	(248,242)
Shares, Outstanding, Ending Balance at Mar. 31, 2018		2,369,648
Stock Compensation Expense			72,500		72,500
Net Loss				(91,401)	(91,401)
Stockholders' Equity Attributable to Parent, Ending Balance at Jun. 30, 2018		$ 2,370	13,627,024	(13,896,537)	(267,143)
Shares, Outstanding, Ending Balance at Jun. 30, 2018		2,369,648
Issuance of warrants to purchase common stock			4,550		4,550
Net Loss				(34,807)	(34,807)
Stockholders' Equity Attributable to Parent, Ending Balance at Sep. 30, 2018		$ 2,370	13,631,574	(13,931,344)	(297,400)
Shares, Outstanding, Ending Balance at Sep. 30, 2018		2,369,648
Net Loss			33,123	(74,345)	(41,222)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2018		$ 2,370	13,664,697	(14,005,689)	(338,622)
Shares, Outstanding, Ending Balance at Dec. 31, 2018		2,369,648
Exercise of rights to purchase warrants to purchase shares of common stock, Amount		$ 210	1,892		2,102
Exercise of rights to purchase warrants to purchase shares of common stock, Shares		210,000
Issuance of warrants to purchase common stock			26,773		26,773
Issuance of Series A Convertible Preferred Stock for cash, Amount	$ 30		2,989,970		2,990,000
Issuance of Series A Convertible Preferred Stock for cash, Shares	29,900
Series A Preferred Stock dividend payable				(18,552)	(18,552)
Net Loss				(44,440)	(44,440)
Stockholders' Equity Attributable to Parent, Ending Balance at Mar. 31, 2019	$ 30	$ 2,580	16,683,332	(14,068,681)	2,617,261
Shares, Outstanding, Ending Balance at Mar. 31, 2019	29,900	2,579,648
Issuance of Series A Convertible Preferred Stock for cash, Amount	$ 36		3,624,964		3,625,000
Issuance of Series A Convertible Preferred Stock for cash, Shares	36,250
Series A Preferred Stock dividend payable				(26,425)	(26,425)
Stock Compensation Expense			834,186		834,186
Net Loss				(896,815)	(896,815)
Stockholders' Equity Attributable to Parent, Ending Balance at Jun. 30, 2019	$ 66	$ 2,580	21,142,482	(14,991,921)	6,153,207
Shares, Outstanding, Ending Balance at Jun. 30, 2019	66,150	2,579,648
Exercise of warrants, Amount		$ 147	8,778		8,925
Exercise of warrants, Shares		147,021
Issuance of Series B Convertible Preferred Stock for cash, Amount	$ 90		449,910		450,000
Issuance of Series B Convertible Preferred Stock for cash, Shares	90,000
Series A Preferred Stock dividend payable				(50,020)	(50,020)
Series B Preferred Stock dividend payable				(2,232)	(2,232)
Stock Compensation Expense			37,961		37,961
Net Loss				(146,466)	(146,466)
Stockholders' Equity Attributable to Parent, Ending Balance at Sep. 30, 2019	$ 156	$ 2,727	21,639,131	(15,190,639)	6,451,375
Shares, Outstanding, Ending Balance at Sep. 30, 2019	156,150	2,726,669
Issuance of Series B Convertible Preferred Stock for cash, Amount	$ 10		49,990		50,000
Issuance of Series B Convertible Preferred Stock for cash, Shares	10,000
Series A Preferred Stock dividend payable				(50,020)	(50,020)
Series B Preferred Stock dividend payable				(3,509)	(3,509)
Stock Compensation Expense			2,007		2,007
Net Loss				(148,384)	(148,384)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2019	$ 166	$ 2,727	$ 21,691,128	$ (15,392,552)	$ 6,301,469
Shares, Outstanding, Ending Balance at Dec. 31, 2019	166,150	2,726,669

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities
Net Loss	$ (1,236,105)	$ (220,621)
Adjustments to Reconcile Loss to Net Cash Used in Operating Activities:
Stock Compensation Expense	874,154	72,500
Financing Cost - Issuance of Warrants to Purchase Common Stock	26,773	37,673
Changes in Operating Assets and Liabilities:
Prepaid Expenses	(9,583)	0
Accounts Payable to Related Parties	(191,776)	71,251
Accounts Payable	(74,965)	7,025
Net Cash Used in Operating Activities	(611,502)	(32,172)
Cash Flows From Investing Activities
Investment in Ablis	(399,200)	0
Investment in Bendistillery and Bend Spirits	(1,497,000)	0
Receipt of CBD Lion Loan Repayments	100,000	0
Loan to CBD Lion	(300,000)	0
Net Cash Used in Investing Activities	(2,096,200)	0
Cash Flows From Financing Activities
Financing Cost - Proceeds From Borrowing Under Notes Payable to Related Parties	14,772	30,791
Financing Cost - Repayment of Borrowings Under Notes Payable to Related Parties	(45,562)	0
Financing Cost - Repayment of Interest Payable to Related Parties	(2,606)	0
Financing Cost - Interest Payable to Related Parties	0	1,381
Exercise of Warrants	11,027	0
Issuance of Series A Convertible Preferred Stock	6,615,000	0
Issuance of Series B Convertible Preferred Stock	500,000	0
Net Cash Provided by Financing Activities	7,092,631	32,172
Net Increase/(Decrease) in Cash	4,384,929	0
Cash and Cash Equivalents at Beginning of Year	0	0
Cash and Cash Equivalents at End of Year	4,384,929	0
Supplemental Cash Flow Information
Cash paid for interest	2,606	0
Cash paid for income taxes	$ 0	$ 0

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Disclosure Text Block [Abstract]
Note 1 - Basis of Presentation and Significant Accounting Policies	NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation Our business involves acquiring all or a portion of operating businesses involving the manufacture, sale and distribution of cannabinoid-infused products such as beverages, lotions, oils, hemp joints and cigarettes, tinctures, bath bombs, balms, body washes, gummies, food, other edibles, and non-prescription cannabinoid formulations (a “Canna-Infused Products Company”). In order to consummate a particular acquisition of a Canna-Infused Products Company, management of the Company is open-minded to the concept of also acquiring all or a portion of one or more operating businesses and/or assets that are related to such Canna-Infused Products Company, for example operating businesses and/or assets involving distilled spirits, beer, wine, paraphernalia and real estate. To date, we have acquired 100% of the ownership interests in one Canna-Infused Products Company d/b/a Lifted Made, 4.99% of the ownership interests in a second Canna-Infused Products Company called Ablis Holding Company ("Ablis"), and 4.99% of the ownership interests in two other businesses that manufacture distilled spirits called Bendistillery Inc. ("Bendistillery") and Bend Spirits, Inc. ("Bend Spirits"). For more information, please refer to “Description of the Business of Acquired Sales Corp. "The Lifted Made Business" ITEM 1. BUSINESS” above. Use of Estimates Cash and Cash Equivalents Notes Receivable Fair Value of Financial Instruments Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair-value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows: Level 1 – Level 2 – Level 3 – Investments Income Taxes Basic and Diluted Earnings (Loss) Per Common Share For the Year Ended December 31, 2019 2018 Net Loss $ (1,236,105) $ (220,621) Weighted-Average Shares Outstanding 2,577,349 2,369,648 Basic and Diluted Earnings Loss per Share $ (0.48) $ (0.09) At December 31, 2019, there were outstanding options to purchase 1,586,619 shares of common stock at between $0.001 and $2.00 per share, (b) rights to purchase warrants to purchase 2,625,000 shares of common stock at between $0.01 and $1.85 per share, and (c) financing warrants to purchase 31,250 shares of common stock at $0.03. As of the date of this report, none of these outstanding options, rights to purchase warrants or financing warrants have been exercised into shares of common stock. However, all of them may be exercised at any time in the sole discretion of the holder except for the rights to purchase warrants to purchase 1.25 million shares of our commons stock, are not exercisable until a performance contingency is met. At December 31, 2019, the Company had Series A Preferred Stock In comparison, at December 31, 2018, there were outstanding options to purchase 1,186,132 shares of common stock at between $0.001 and $0.60 per share, (b) rights to purchase warrants to purchase 2,950,000 shares of common stock at between $0.01 and $1.85 per share, and (c) financing warrants to purchase 37,500 shares of common stock at $0.03. As of the date of this report, none of these outstanding options, rights to purchase warrants or financing warrants have been exercised into shares of common stock. However, all of them may be exercised at any time in the sole discretion of the holder except for the rights to purchase warrants to purchase 1.25 million shares of our commons stock, are not exercisable until a performance contingency is met. Recent Accounting Pronouncements – Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2018, the FASB issued ASU 2018-15, “Intangibles - Goodwill and Other - Internal Use Software (Subtopic 250-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs for internal-use software. The accounting for any hosting contract is unchanged. ASU 2018-15 is effective on January 1, 2020 with early adoption permitted, including adoption in any interim period. The Company is currently evaluating the impact of ASU 2019-12 on its financial statements. Off Balance Sheet Arrangements

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	12 Months Ended
	Dec. 31, 2019
Disclosure Text Block [Abstract]
Note 2 - Risks and Uncertainties	NOTE 2 - RISKS AND UNCERTAINTIES Going Concern – As of December 31, 2019, the Company did not have any business or any sources of revenue. The Company currently has no revenue-generating subsidiaries. Management plans to sustain the Company as a going concern by taking the following actions: (1) acquiring and/or developing profitable businesses that will create positive income from operations; and/or (2) completing private placements of the Company’s common stock and/or preferred stock. Management believes that by taking these actions, the Company will be provided with sufficient future operations and cash flow to continue as a going concern. However, there can be no assurances or guarantees whatsoever that the Company will be successful in consummating such actions on acceptable terms, if at all. Moreover, any such actions can be expected to result in substantial dilution to the existing shareholders of the Company. The Company’s investments in Ablis, Bendistillery and Bend Spirits made the Company a minority owner of these companies. As a minority owner, the Company is not able to recognize any portion of Ablis’, Bendistillery’s or Bend Spirits’ revenues or earnings in the Company’s financial statements. The Company monitors its investments in Ablis, Bendistillery and Bend Spirits, and from time to time and will evaluate whether there has been a potential impairment of value.

Note 3 - The Company's Investme

Note 3 - The Company's Investments In Ablis, Bendistillery And Bend Spirits	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Note 3 - The Company’s Investments In Ablis, Bendistillery And Bend Spirits	NOTE 3 – THE COMPANY’S INVESTMENTS IN ABLIS, BENDISTILLERY AND BEND SPIRITS On April 30, 2019, the Company purchased 4.99% of the common stock of each of Ablis Holding Company, Bendistillery Inc., and Bend Spirits, Inc. for an aggregate purchase price of $1,896,200. The Company’s investments in Ablis, Bendistillery and Bend Spirits made the Company a minority owner of these companies. As a minority owner, the Company will not be able to recognize any portion of Ablis’, Bendistillery’s or Bend Spirits’ revenues or earnings in the Company’s financial statements. Pursuant to US GAAP, the Company is obligated to periodically review its investments. The Company has limited ability to comment on these companies’ operations and financial performance. The Company’s ability to review the financial performance of its investment in these companies is limited: the financial statements of these companies are not audited; the Company is not active in the management of these companies; and these companies have not held meetings of their boards of directors since the closing of our investment. Consequently, the Company’s assessment of these companies is inherently limited to infrequent and relatively brief conversations with officers of these companies, and to reviews of unaudited financial statements that are delivered to us on an irregular basis. Based on the financial and non-financial information regarding the year ended December 31, 2019, that the management of Ablis, Bendistillery and Bend Spirits provided to the Company in a conference call held on March 9, 2020, the Company has concluded that an impairment of its investment in these companies as of December 31, 2019 is not warranted. The factors that led the Company to the conclusion that an impairment of its investment in these companies has of December 31, 2019 is not warranted includes, among other things: positive sales trends during recent months; indications of the Companies’ ability to maintain profitability; and certain initiatives that are being undertaken by these companies in regard to leadership, sales representatives, and product distribution and pricing.

Note 4 - Notes Receivable

Note 4 - Notes Receivable	12 Months Ended
	Dec. 31, 2019
Disclosure Text Block [Abstract]
Note 4 - Notes Receivable	NOTE 4 – NOTES RECEIVABLE CBD Lion LLC On August 8, 2019, the Company made an unsecured $300,000 loan to Lion (the “Loan”) evidenced by a promissory note (the “Note”) in connection with the proposed Merger Agreement with Lion. Per the terms of the Note, if the Transaction did not close and the merger agreement were terminated, then the Loan was to be repaid by Lion to the Company in six equal monthly installments of principal, together with accrued interest at the rate of 6% per year, with the first such installment due and payable by Lion to the Company on the first day of the first calendar month following the termination of the merger agreement. The Merger Agreement was terminated by the Company on November 14, 2019 and the Note became payable. During December 2019, the principal of the Note was repaid by Lion down to $200,000, and Lion also paid the accrued interest on the Note of $6,945. Due to termination of the Merger Agreement, and per Section 5.15(b) of the Merger Agreement, as of December 31, 2019 the Company owed CBD Lion $31,500 for reimbursement of professional fees related to the audit of CBD Lion. This left Lion with a net balance owed to the Company of $168,500 as of December 31, 2019. In March 2020, Lion and the Company agreed that the repayment of such $168,500 will be made in eleven equal monthly installments of principal due and payable by Lion to the Company on the first day of each calendar month starting on April 1, 2020, and that no additional interest will accrue. Imputed interest on the remaining amounts owed by Lion to the Company will be evaluated during the first quarter of 2020. The William Noyes Webster Foundation, Inc. The Foundation, a non-profit Massachusetts corporation, has received a provisional registration from the Commonwealth of Massachusetts to own and operate a medical marijuana cultivation facility in Plymouth, Massachusetts, and a medical marijuana dispensary in Dennis, Massachusetts. Jane W. Heatley (“Heatley”) is the founder and a member of the board of directors of the Foundation. Teaming Agreement Promissory Note Between April and July 2015, the Company loaned an additional $135,350 to the Foundation, evidenced by the Note and secured by the Security Agreement. Following such additional loans, the principal of the loan from the Company to the Foundation, evidenced by the Note and secured by the Security Agreement, is now $737,850. The principal balance outstanding under the Note bore interest at the rate of 12.5% per annum, compounded monthly. It was contemplated that the first payment of accrued interest by the Foundation under the Note would be made as soon after the Foundation commences operations of the Plymouth Cultivation Facility and the Dennis Dispensary as the Foundation's cash flows shall reasonably permit, but in any event no later than one year after the Foundation commences operations. The principal of the Note would be payable in eight consecutive equal quarterly installments, commencing on the last day of the calendar quarter in which the Foundation commences operations. Principal on the Note and related accrued interest would be considered past due if the aforementioned payments were not received by their due dates. Uncollectable Note and Interest Receivable

Note 5 - Transactions with Rela

Note 5 - Transactions with Related Parties	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Note 5 - Transactions with Related Parties	NOTE 5 – TRANSACTIONS WITH RELATED PARTIES On June 21, 2016, a company affiliated with Gerard M. Jacobs, Chief Executive Officer of Acquired Sales, made a non-interest bearing loan of $4,000 to the Company, which is payable upon demand. At December 31, 2019, there are no expense reimbursements owed to Gerard M. Jacobs. In comparison, at December 31, 2018, there were expense reimbursements owed to Gerard M. Jacobs totaling $24,583. At December 31, 2019, there was a prepaid consulting fee of $7,500 paid to Gerard M. Jacobs. In comparison, at December 31, 2018, there were no prepaid consulting fees paid to Gerard M. Jacobs. At December 31, 2019, there are no independent contractor fees or expense reimbursements owed to William C. Jacobs. In comparison, at December 31, 2018, there were independent contractor fees of $160,000 and expense reimbursements of $4,417 owed to William C. Jacobs totaling $164,417. William C. Jacobs is the son of Gerard M. Jacobs, Chief Executive Officer of Acquired Sales, and the nephew of director James S. Jacobs. Financing Warrants As of December 31, 2018, a total of $30,791 had been borrowed by AQSP on such terms, and warrants to purchase 25,000 shares of common stock of AQSP had been issued to Joshua A. Bloom and warrants to purchase 12,500 shares of common stock of AQSP had been issued to Gerard M. Jacobs. These loans were fully repaid by the Company on March 13, 2019. The warrants to purchase common stock that were issued to Joshua A. Bloom and Gerard M. Jacobs on July 16, 2018 and July 18, 2018 were valued using the Black-Scholes valuation model as of the date they were issued. The values of these warrants were fully expensed because the notes were payable upon demand. The expense recognized related to the issuance of the warrants to Joshua A. Bloom on July 16, 2018 was $3,250. Gerard M. Jacobs’ warrants were issued to him on July 18, 2018, and the expense recognized related to the issuance of these warrants was $1,300. The warrants to purchase common stock that were issued to Gerard M. Jacobs on November 8, 2018, and to Joshua A. Bloom on November 12, 2018, were valued using the Black-Scholes valuation model, which incorporated the following assumptions: expected future stock volatility 465%; risk-free interest rates of 2.98% and 2.94%, respectively; dividend yield of 0% and an expected terms of 2.38 years and 2.37 years, respectively. The expected future stock volatility was based on the volatility of Acquired Sales Corp.’s historical stock prices. The risk-free interest rate was based on the U.S. Federal treasury rate for instruments due over the expected term of the warrants. The expected term of each warrant was based on the midpoint between the date the warrant vests and the contractual term of the warrant. The values of the warrants were fully expensed as of the date of issuance because they are payable upon demand. The expense recognized related to the issuance of the warrants to Gerard M. Jacobs on November 8, 2018 was $11,250. The expense recognized related to the issuance of the warrants to Joshua A. Bloom on November 12, 2018 was $21,874.

Note 6 - Shareholders' Equity

Note 6 - Shareholders' Equity	12 Months Ended
	Dec. 31, 2019
Disclosure Text Block [Abstract]
Note 6 - Shareholders' Equity	NOTE 6 – SHAREHOLDERS’ EQUITY Share-Based Compensation Share-Based Compensation in 2019 The following is a summary of share-based compensation, stock option and warrant activity as of December 31, 2019 and changes during the year then ended: Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Exercisable Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants Outstanding, December 31, 2018 2,923,632 $ 0.87 4.93 $ 2,410,100 Financing Warrants Issued During Q1 2019 18,750 Warrants Granting the Right to Purchase Shares of Common Stock Issued During Q2 2019 410,942 Options that Expired During Q2 2019 (9,434) Rights to Purchase Warrants to Purchase Shares of Common Stock Exercised During Q1 2019 (210,000) Warrants Granting the Right to Purchase Shares of Common Stock Issued During Q3 2019 5,400 Warrants exercised during Q3 2019 (147,021) Warrants Granting the Right to Purchase Shares of Common Stock Issued During Q4 2019 600 Exercisable Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants Outstanding, December 31, 2019 2,992,869 $ 0.97 3.47 $ 4,570,144 Outstanding Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants, December 31, 2019 4,242,869 $ 1.23 3.92 $ 5,382,644 Share-Based Compensation in 2018 On April 1, 2018, we issued to director James S. Jacobs and to William C. Jacobs, then an independent contractor and now our President and CFO, rights to purchase warrants, for an aggregate purchase price of $2.00, an aggregate of 250,000 shares of common stock of the Company (40,000 to James S. Jacobs, and 210,000 to William C. Jacobs), at an exercise price of $0.01 per share, such warrants to be fully vested and to be exercisable on or prior to December 31, 2024. Using the Black-Scholes valuation model, we recorded total stock compensation expense of $72,500 related to these rights to purchase warrants; this consists of $11,600 of stock compensation for the rights to purchase warrants issued to James S. Jacobs, and $60,900 of stock compensation for the rights to purchase warrants issued to William C. Jacobs.

Note 7 - Income Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Disclosure Text Block [Abstract]
Note 7 - Income Taxes	NOTE 7 – INCOME TAXES On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act reduced the U.S. federal statutory tax rate, broadened the corporate tax base through the elimination or reduction of deductions, exclusions, and credits, limited the ability of U.S. corporations to deduct interest expense, and transitioned to a territorial tax system which allows for the repatriation of foreign earnings to the U.S. with a 100% federal dividends received deduction prospectively. In addition, the Tax Act required a one-time transitional tax on foreign cash equivalents and previously unremitted earnings. Several of the new provisions enacted as part of the Tax Act require clarification and guidance from the U.S. Internal Revenue Service (“IRS”) and Treasury Department. These or other changes in U.S. tax laws could impact our profits, effective tax rate, and cash flows. During the years ended December 31, 2019 and 2018, the Company did not incur any current tax on its continuing operations and there was no deferred tax provision or benefit from continuing operations. At December 31, 2019, the Company has total U.S. Federal net operating loss carry forwards of $2,440,592. $1,968,244 of the total net operating loss carryforwards were generated from tax years prior to January 1, 2018 and expire between December 31, 2029 and December 31, 2037. The remaining $472,349 in net operating loss carryforwards have an indefinite carryforward period and can only offset 80% of taxable income. As of December 31, 2019, the Company had no unrecognized tax benefits that, if recognized, would affect the Company’s effective income tax rate over the next 12 months. The Company currently believes that all significant filing positions are highly certain and that all of its significant income tax filing positions and deductions would be sustained upon audit. Therefore, the Company has no significant reserves for uncertain tax positions and no adjustments to such reserves were required by generally accepted accounting principles. The Company’s policy is to recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. The Company’s tax returns are subject to examination for the years ended December 31, 2014 through 2018. A reconciliation of the amount of tax benefit computed using the U.S. federal statutory income tax rate to the provision for income taxes on continuing operations is as follows: For the Years Ended December 31, 2019 2018 Tax expenses (benefit) at statutory rate (21%) $ (254,542) $ (46,330) Non-deductible expenses $ 2,606 276 Revision of prior years' deferred tax assets $ 12,600 (30,034) Change in valuation allowance $ 239,337 (1,488,585) Provision for Income Taxes $ - $ - The decrease in the valuation allowance in 2018 was the result of the decrease in corporate tax rate as a result of the Tax Act; had the corporate tax rate stayed the same in 2018 as it were in 2017, the valuation allowance would have increased by $111,835 in 2018. The tax effects of temporary differences and carry forwards that gave rise to the net deferred income tax asset as of December 31, 2019 and 2018 were as follows: December 31, 2019 2018 Operating loss carry forwards $ 484,157 $ 428,393 Stock-based compensation 1,816,938 2,874,127 Other 0 233 Less: Valuation allowance (2,301,095) (2,061,891) Net Deferred Income Tax Asset $ - - The deferred tax asset valuation allowance increased by $239,204 and decreased by $1,488,585 during the years ended December 31, 2019 and 2018, respectively.

Note 8 - Contingent Contractual

Note 8 - Contingent Contractual Obligations and Commercial Commitments	12 Months Ended
	Dec. 31, 2019
Disclosure Text Block [Abstract]
Note 8 - Contingent Contractual Obligations and Commercial Commitments	NOTE 8 – CONTINGENT CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENTS Payment of Finders’ Fees Related to Ablis The Company has agreed to pay finders’ fees to two finders in regard to the potential purchase of an additional 15% of the stock of Ablis. The Company has agreed to pay those two finders additional warrants to purchase shares of common stock of the Company at an exercise price of $1 per share exercisable at any time on or before April 30, 2024; in the event that the Company closes on the purchase of up to an additional 15% of the common stock of Ablis, then the total amount of such warrants will be 2,814 unregistered shares of common stock of AQSP at an exercise price of $1 per share for each additional one percent of Ablis’ common stock so purchased (a maximum issuance of warrants to purchase an aggregate of 42,210 unregistered shares of common stock of the Company at an exercise price of $1 per share). Previously, on April 30, 2019, the Company issued warrants to purchase 14,042 unregistered shares of common stock of the Company, issued to the two finders (7,021 warrants were issued to each finder) in regard to the purchase of 4.99% of the stock of Ablis. Using the Black-Scholes valuation model, these warrants were valued and expensed as being worth $40,708. Payment of Brokers’ Fees Related to the Sale of Preferred Stock The Company has committed to pay brokers’ fees in regard to the capital being raised for the Company by such brokers in the Company’s private placements of preferred stock, such fee to consist of warrants to purchase unregistered shares of common stock of the Company at an exercise price equal to the conversion price per share of such preferred stock, exercisable at any time during a five year period; the number of such shares will be calculated as six percent of the aggregate capital raised by such brokers in the private placement of preferred stock divided by the conversion price per share of such preferred stock. In 2019, warrants to purchase 402,900 unregistered shares of common stock of the Company were issued to these brokers. Using the Black-Scholes valuation model, these warrants were valued and expensed as being worth $833,446. Potential Issuance of Warrants to Purchase Shares of Common Stock of the Company The Compensation Committee of the Company's Board of Directors may, from time to time, recommend that certain warrants to purchase shares of common stock of the Company should be issued to new or current members of the Company’s Board of Directors, to officers and employees of the Company and its subsidiaries, or to members of any advisory board or consultants to the Company. Amounts Payable to Gerard M. Jacobs and William C. Jacobs The Company’s CEO Gerard M. Jacobs runs the Company’s operations on a part-time basis and is compensated with equity. Gerard M. Jacobs has not historically received cash compensation, and, historically, the Company’s President and CFO William C. “Jake” Jacobs has worked for $5,000 per month. Effective as of June 19, 2019 through the earlier of the closing of the Company’s acquisition of CBD Lion LLC, which is now terminated or the closing of the Company’s acquisition of Warrender Enterprise Inc. d/b/a Lifted Made (formerly d/b/a Lifted Liquids) (“Lifted”), the Company has agreed to pay Gerard M. Jacobs and William C. “Jake” Jacobs consulting fees of $7,500 and $5,000 per month, respectively. In addition, upon the closing of the acquisition described herein, their salaries, equity incentives, expense reimbursements and bonuses will increase. There are also to be significant bonuses awarded to Gerard M. Jacobs and William C. “Jake” Jacobs in the event that the Company closes on the acquisition of Lifted, and in the event that the Company raises $15 million and $25 million, as described in the current report on Form 8-K, and its exhibit, filed with the SEC on or about June 25, 2019. Please note that as of December 31, 2019, the Company had not yet closed on its acquisition of Lifted, and the Company had not raised $15 million and $25 million, so no accruals for the bonuses triggered by these events had been made. As of March 22, 2020, the Company has closed on the acquisition of Lifted, and the bonuses have been accrued for but have not yet paid. The Company has not yet raised $15 million or $25 million. Professional Contracts In June 2019, the Company executed annual engagement contracts with its stock transfer agent and its securities attorney; the Company has a prepaid balance with its stock transfer agent.

Note 9 - Subsequent Events

Note 9 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Note 9 - Subsequent Events	NOTE 9 – SUBSEQUENT EVENTS Subsequent to the 12 month period ended December 31, 2019, all necessary Board approvals, Board Investment Committee approvals and stockholder approvals for the Lifted transaction were given on January 4, 2020, and January 10, 2020, respectively. Acquisition of 100% of Warrender Enterprise Inc. d/b/a Lifted Made (formerly d/b/a Lifted Liquids) On February 24, 2020 we closed on the acquisition of 100% of the ownership of CBD-infused products maker Warrender Enterprise Inc. d/b/a Lifted Made (formerly d/b/a Lifted Liquids) of Zion, Illinois (the “Merger”), for consideration of (1) $3,750,000 in cash, (2) $3,750,000 in the form of a secured promissory note, (3) 3,900,455 shares of unregistered common stock of the Company (the "Stock Consideration"), (4) 645,000 shares of unregistered common stock of the Company that constitute deferred contingent compensation to be issued and delivered to certain persons specified by Nicholas S. Warrender in a schedule delivered by Nicholas S. Warrender to the Company at the closing of the Merger, and (5) warrants to purchase an aggregate of 1,820,000 shares of unregistered common stock of the Company at an exercise price of $5.00 per share that will be issued and delivered to certain persons specified by Nicholas S. Warrender in a schedule delivered by Nicholas S. Warrender to the Company at the closing of the Merger. Pursuant to the Merger, Lifted Liquids, Inc. d/b/a Lifted Made, an Illinois corporation ("Lifted" or "Lifted Made"), is now operating as a wholly-owned subsidiary of the Company, led by Nicholas S. Warrender as Lifted's CEO and also as Vice Chairman and Chief Operating Officer of Acquired Sales. Nicholas S. Warrender shall, subject to certain conditions, enjoy so-called “piggyback registration rights” and "demand registration rights" in regard to the Stock Consideration, pursuant to a Registration Rights Agreement. From the date of acquisition (February 24, 2020) on, Lifted will be fully consolidated within the Company’s financial statements. Remaining Payment Obligations of CBD Lion to the Company On August 8, 2019, the Company made an unsecured $300,000 loan to Lion (the “Loan”) evidenced by a promissory note (the “Note”) in connection with the proposed Merger Agreement with Lion. Per the terms of the Note, if the Transaction did not close and the merger agreement were terminated, then the Loan was to be repaid by Lion to the Company in six equal monthly installments of principal, together with accrued interest at the rate of 6% per year, with the first such installment due and payable by Lion to the Company on the first day of the first calendar month following the termination of the merger agreement. The Merger Agreement was terminated by the Company on November 14, 2019 and the Note became payable. During December 2019, the principal of the Note was repaid by Lion down to $200,000, and Lion also paid the accrued interest on the Note of $6,945. Due to termination of the Merger Agreement, and per Section 5.15(b) of the Merger Agreement, as of December 31, 2019 the Company owed CBD Lion $31,500 for reimbursement of professional fees related to the audit of CBD Lion. This left Lion with a net balance owed to the Company of $168,500 as of December 31, 2019. In March 2020, Lion and the Company agreed that the repayment of such $168,500 will be made in eleven equal monthly installments of principal due and payable by Lion to the Company on the first day of each calendar month starting on April 1, 2020, and that no additional interest will accrue. Imputed interest on the remaining amounts owed by Lion to the Company will be evaluated during the first quarter of 2020. Payment of Dividends to Holders of Series A Preferred Stock Between February 28, 2020 and March 21, 2020, the Company made payments of dividends totaling $89,700 to holders of the Company’s Series A Convertible Preferred Stock.

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Policy Text Block [Abstract]
Basis of Presentation	Basis of Presentation Our business involves acquiring all or a portion of operating businesses involving the manufacture, sale and distribution of cannabinoid-infused products such as beverages, lotions, oils, hemp joints and cigarettes, tinctures, bath bombs, balms, body washes, gummies, food, other edibles, and non-prescription cannabinoid formulations (a “Canna-Infused Products Company”). In order to consummate a particular acquisition of a Canna-Infused Products Company, management of the Company is open-minded to the concept of also acquiring all or a portion of one or more operating businesses and/or assets that are related to such Canna-Infused Products Company, for example operating businesses and/or assets involving distilled spirits, beer, wine, paraphernalia and real estate. To date, we have acquired 100% of the ownership interests in one Canna-Infused Products Company d/b/a Lifted Made, 4.99% of the ownership interests in a second Canna-Infused Products Company called Ablis Holding Company ("Ablis"), and 4.99% of the ownership interests in two other businesses that manufacture distilled spirits called Bendistillery Inc. ("Bendistillery") and Bend Spirits, Inc. ("Bend Spirits"). For more information, please refer to “Description of the Business of Acquired Sales Corp. "The Lifted Made Business" ITEM 1. BUSINESS” above.
Use of Estimates	Use of Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Notes Receivable	Notes Receivable
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair-value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows: Level 1 – Level 2 – Level 3 –
Investments	Investments
Income Taxes	Income Taxes
Basic and Diluted Earnings (Loss) Per Common Share	Basic and Diluted Earnings (Loss) Per Common Share For the Year Ended December 31, 2019 2018 Net Loss $ (1,236,105) $ (220,621) Weighted-Average Shares Outstanding 2,577,349 2,369,648 Basic and Diluted Earnings Loss per Share $ (0.48) $ (0.09) At December 31, 2019, there were outstanding options to purchase 1,586,619 shares of common stock at between $0.001 and $2.00 per share, (b) rights to purchase warrants to purchase 2,625,000 shares of common stock at between $0.01 and $1.85 per share, and (c) financing warrants to purchase 31,250 shares of common stock at $0.03. As of the date of this report, none of these outstanding options, rights to purchase warrants or financing warrants have been exercised into shares of common stock. However, all of them may be exercised at any time in the sole discretion of the holder except for the rights to purchase warrants to purchase 1.25 million shares of our commons stock, are not exercisable until a performance contingency is met. At December 31, 2019, the Company had Series A Preferred Stock In comparison, at December 31, 2018, there were outstanding options to purchase 1,186,132 shares of common stock at between $0.001 and $0.60 per share, (b) rights to purchase warrants to purchase 2,950,000 shares of common stock at between $0.01 and $1.85 per share, and (c) financing warrants to purchase 37,500 shares of common stock at $0.03. As of the date of this report, none of these outstanding options, rights to purchase warrants or financing warrants have been exercised into shares of common stock. However, all of them may be exercised at any time in the sole discretion of the holder except for the rights to purchase warrants to purchase 1.25 million shares of our commons stock, are not exercisable until a performance contingency is met.
Recent Accounting Pronouncements	Recent Accounting Pronouncements – Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2018, the FASB issued ASU 2018-15, “Intangibles - Goodwill and Other - Internal Use Software (Subtopic 250-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs for internal-use software. The accounting for any hosting contract is unchanged. ASU 2018-15 is effective on January 1, 2020 with early adoption permitted, including adoption in any interim period. The Company is currently evaluating the impact of ASU 2019-12 on its financial statements.
Off Balance Sheet Arrangements	Off Balance Sheet Arrangements

Note 1 - Basis of Presentatio_3

Note 1 - Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Table Text Block Supplement [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table summarizes the calculations of basic and diluted earnings (loss) per common share for the years ended December 31, 2019 and 2018: For the Year Ended December 31, 2019 2018 Net Loss $ (1,236,105) $ (220,621) Weighted-Average Shares Outstanding 2,577,349 2,369,648 Basic and Diluted Earnings Loss per Share $ (0.48) $ (0.09)

Note 6 - Shareholders' Equity (

Note 6 - Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Table Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Stock Options and Warrant Activity	The following is a summary of share-based compensation, stock option and warrant activity as of December 31, 2019 and changes during the year then ended: Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Exercisable Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants Outstanding, December 31, 2018 2,923,632 $ 0.87 4.93 $ 2,410,100 Financing Warrants Issued During Q1 2019 18,750 Warrants Granting the Right to Purchase Shares of Common Stock Issued During Q2 2019 410,942 Options that Expired During Q2 2019 (9,434) Rights to Purchase Warrants to Purchase Shares of Common Stock Exercised During Q1 2019 (210,000) Warrants Granting the Right to Purchase Shares of Common Stock Issued During Q3 2019 5,400 Warrants exercised during Q3 2019 (147,021) Warrants Granting the Right to Purchase Shares of Common Stock Issued During Q4 2019 600 Exercisable Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants Outstanding, December 31, 2019 2,992,869 $ 0.97 3.47 $ 4,570,144 Outstanding Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants, December 31, 2019 4,242,869 $ 1.23 3.92 $ 5,382,644

Note 7 - Income Taxes (Tables)

Note 7 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Table Text Block Supplement [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the amount of tax benefit computed using the U.S. federal statutory income tax rate to the provision for income taxes on continuing operations is as follows: For the Years Ended December 31, 2019 2018 Tax expenses (benefit) at statutory rate (21%) $ (254,542) $ (46,330) Non-deductible expenses $ 2,606 276 Revision of prior years' deferred tax assets $ 12,600 (30,034) Change in valuation allowance $ 239,337 (1,488,585) Provision for Income Taxes $ - $ -
Schedule of Deferred Tax Assets	The tax effects of temporary differences and carry forwards that gave rise to the net deferred income tax asset as of December 31, 2019 and 2018 were as follows: December 31, 2019 2018 Operating loss carry forwards $ 484,157 $ 428,393 Stock-based compensation 1,816,938 2,874,127 Other 0 233 Less: Valuation allowance (2,301,095) (2,061,891) Net Deferred Income Tax Asset $ - -

Note 1 - Basis of Presentatio_4

Note 1 - Basis of Presentation and Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Apr. 30, 2019	Apr. 02, 2018
Convertible Preferred Stock, Shares Reserved for Future Issuance	6,615,000
Stock issued for cash , Value	$ 100,000
Stock issued for cash , Shares	500,000
Share Price	$ 5			$ 2
Ablis
Ownership interests			4.99%
Bendistillery
Ownership interests			4.99%
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,586,619	1,186,132
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,625,000	2,950,000
Financing Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	31,250	37,500

Note 1 - Basis of Presentatio_5

Note 1 - Basis of Presentation and Significant Accounting Policies: Basic and Diluted Earnings (Loss) Per Common Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Text Block [Abstract]
Net Loss	$ (1,236,105)	$ (220,621)
Weighted Average Shares Outstanding	2,577,349	2,369,648
Basic and Diluted Earnings Loss per Share	$ (0.48)	$ (0.09)

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Text Block [Abstract]
Accumulated deficit	$ (15,392,552)	$ (14,005,689)
Net Loss	$ (1,236,105)	$ (220,621)

Note 3 - The Company's Invest_2

Note 3 - The Company's Investments In Ablis, Bendistillery And Bend Spirits (Details) - Bendistillery	Apr. 30, 2019USD ($)
Ownership interests	4.99%
Purchse price	$ 1,896,200

Note 4 - Notes Receivable (Deta

Note 4 - Notes Receivable (Details) - USD ($)	Aug. 08, 2019	Sep. 01, 2015	Dec. 31, 2019	Jul. 31, 2014	Jul. 31, 2015	Dec. 31, 2015	Jul. 14, 2014
William Noyes Webster Foundation Inc | Secured Promissory Note
Debt Instrument, Face Amount							$ 1,500,000
Note receivable payment				$ 602,500	$ 135,350
Advances				600,000
Note Receivable						$ 737,850
Debt Instrument, Interest Rate, Stated Percentage						12.50%
Bad debt expense		$ 737,850
William Noyes Webster Foundation Inc | Secured Promissory Note | Payment To Consultant
Advances				$ 2,500
William Noyes Webster Foundation Inc | Secured Promissory Note | Unfunded Portion of Note
Debt Instrument, Face Amount							$ 897,500
William Noyes Webster Foundation Inc | Interest receivable {1}
Bad debt expense		$ 97,427
CBD Lion
Advances			$ 168,500
Loan	$ 300,000
Interest rate	6.00%
Payment of loan			200,000
Accrued interest			6,945
Reimbursement of professional fees			$ 31,500

Note 5 - Amounts Owed To Relate

Note 5 - Amounts Owed To Related Parties (Details) - USD ($)	Jul. 13, 2019	Nov. 12, 2018	Nov. 08, 2018	Jul. 18, 2018	Jul. 16, 2018	Mar. 31, 2019	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 21, 2016
Issuance of warrants to purchase common stock						$ 26,773	$ 4,550
Gerard M. Jacobs
Due to Other Related Parties, Current										$ 4,000
Due to Related Parties, Current								$ 0	$ 24,583
Prepaid consulting fee								7,500	0
William C. Jacobs
Due to Related Parties, Current								0	164,417
William C. Jacobs | Independent contractor fees
Due to Related Parties, Current								0	160,000
William C. Jacobs | Expense reimbursements
Due to Related Parties, Current								$ 0	4,417
Warrant 1 | Gerard M. Jacobs
Warrants issued				12,500
Issuance of warrants to purchase common stock			$ 11,250	$ 1,300
Volatility rate			465.00%
Risk-free interest rates			2.98%
Dividend yield			0.00%
Expected terms			2 years 4 months 17 days
Warrant 1 | Joshua A. Bloom
Warrants issued					25,000
Issuance of warrants to purchase common stock		$ 21,874			$ 3,250
Volatility rate		465.00%
Risk-free interest rates		2.94%
Dividend yield		0.00%
Expected terms		2 years 4 months 13 days
Financing warrants
Debt Instrument, Payment Terms	(1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of AQSP; (2) the borrowings will be evidenced by promissory notes of AQSP, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of AQSP, pursuant to a security agreement signed by AQSP in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to AQSP; (4) the notes shall be due and payable upon demand by the lenders delivered to AQSP; and (5) for each $1,000 loaned by AQSP on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of AQSP, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023.
Long-term Debt, Gross									$ 30,791

Note 6 - Shareholders' Equity_2

Note 6 - Shareholders' Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Apr. 02, 2018
Stock compensation expense	$ 874,154	$ 72,500
Class of Warrant, Outstanding			250,000
Purchase price per share	$ 5		$ 2
Warrant [Member]
Stock compensation expense	$ 874,154
Purchase of warrants	416,942
Share Price	$ 1
William C. Jacobs
Class of Warrant, Outstanding			210,000
Class of Warrant, Exercise Price of Warrants			$ 0.01
James S. Jacobs
Stock compensation expense		11,600
Class of Warrant, Outstanding			40,000
Class of Warrant, Exercise Price of Warrants			$ 0.01
Joshua A. Bloom
Stock compensation expense		$ 60,900

Note 6 - Shareholders' Equity_

Note 6 - Shareholders' Equity: Schedule of Share-based Compensation, Stock Options and Warrant Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Text Block [Abstract]
Exercisable Options, Rights to Purchase Warrants and Financing Warrants Outstanding at beginning	2,923,632
Financing Warrants Issued During Period	18,750
Warrants Granting the Right to Purchase Shares of Common Stock Issued During Period	410,942
Options Expired During Period	(9,434)
Rights to Purchase Warrants to Purchase Shares of Common Stock Exercised During Period	(210,000)
Warrants Granting the Right to Purchase Shares of Common Stock Issued During Period	5,400
Warrants exercised during period	(147,021)
Warrants Granting the Right to Purchase Shares of Common Stock Issued During Period	600
Exercisable Options, Rights to Purchase Warrants and Financing Warrants Outstanding at end	2,992,869	2,923,632
Outstanding Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants	4,242,869
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Weighted Average Exercise Price at beginning	$ 0.87
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Weighted Average Exercise Price at end	0.97	$ 0.87
Outstanding Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants, Weighted Average Exercise Price	$ 1.23
Exercisable Options, Rights to Purchase Warrants and Financing Warrants Outstanding, Weighted Average Remaining Term	3 years 5 months 20 days	4 years 11 months 4 days
Outstanding Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants, Weighted Average Remaining Term	3 years 11 months 1 day
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Intrinsic Value	$ 2,410,100
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Intrinsic Value	4,570,144	$ 2,410,100
Outstanding Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants, Intrinsic Value	$ 5,382,644

Note 7 - Income Taxes (Details)

Note 7 - Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net Operating Loss Carryforwards	$ 2,440,592
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 239,204	$ (1,488,585)
Increase in valuation allowance		$ 111,835
Minimum
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2029
Maximum
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2037

Note 7 - Income Taxes_ Schedule

Note 7 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Text Block [Abstract]
Tax expenses (benefit) at statutory rate (21%)	$ (254,542)	$ (46,330)
Non-deductible expenses	2,606	276
Revision of prior years' deferred tax assets	12,600	(30,034)
Change in valuation allowance	239,337	(1,488,585)
Provision for Income Taxes	$ 0	$ 0

Note 7 - Income Taxes_ Schedu_2

Note 7 - Income Taxes: Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Text Block [Abstract]
Operating loss carry forwards	$ 484,157	$ 428,393
Stock-based compensation	1,816,938	2,874,127
Other	0	233
Less: Valuation allowance	(2,301,095)	(2,061,891)
Net Deferred Income Tax Asset	$ 0	$ 0

Note 8 - Contingent Contractu_2

Note 8 - Contingent Contractual Obligations and Commercial Commitments (Details)	1 Months Ended	12 Months Ended
	Apr. 30, 2019USD ($)shares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)
Consulting fees		$ 112,500	$ 60,000
Warrant [Member]
Purchase of warrants | shares		416,942
CBD Lion
Capital raise		$ 15,000,000
Warrender Enterprise
Capital raise		$ 25,000,000
Ablis
Ownership interests	4.99%
Purchase of warrants | shares	14,042
Value of warrants purchsed	$ 40,708
Ablis
Percntage of common stock purchase		0.15
Additional Percntage of common stock purchase		15.00%
Additional Warrants to purchase | shares		2,814
Maximum warrants issued | shares		42,210
Warrant Exercise price | $ / shares		$ 1
William C. Jacobs
Consulting fees		$ 5,000
Cash compensation received		5,000
James S. Jacobs
Consulting fees		$ 7,500
Brokers | Warrant [Member]
Purchase of warrants | shares		402,900
Value of warrants purchsed		$ 833,446

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details) - USD ($)	Aug. 08, 2019	Mar. 21, 2020	Feb. 24, 2020	Dec. 31, 2019
CBD Lion
Loan	$ 300,000
Interest rate	6.00%
Payment of loan				$ 200,000
Accrued interest				6,945
Reimbursement of professional fees				31,500
Advances				$ 168,500
Subsequent Event | Series A Preferred Stock [Member]
Payment of Dividends		$ 89,700
Subsequent Event | Warrender Enterprise
Cash			$ 3,750,000
Secured promissory note			$ 3,750,000
Stock Consideration			3,900,455
Unregistered common stock			645,000
Purchase of warrants			1,820,000
Share Price			$ 5